Antiplatelets
- Prevent platelet-rich arterial thrombosis
- Aspirin + P2Y12 dominate ACS/PCI care
- Aspirin: irreversible COX-1 inhibition
- P2Y12 drugs differ in potency + reversibility
- Bleeding is the dominant class toxicity
- Little role for treatment of venous thrombosis
- Duration depends on ischemic vs bleeding risk
Class at a glance
- Prevent platelet-rich arterial thrombosis
Pharmacology
- Aspirin: irreversible COX-1 inhibition
- P2Y12 drugs differ in potency + reversibility
Clinical role
- Aspirin + P2Y12 dominate ACS/PCI care
- Little role for treatment of venous thrombosis
Safety / monitoring
- Bleeding is the dominant class toxicity
- Duration depends on ischemic vs bleeding risk
Self-check
- What key adverse effect/risk occurs with Antiplatelets?
Duration depends on ischemic vs bleeding risk.
Drugs in this class (5)
All drug classes · Open the interactive console ↗
